Anti-Interleukin 6 Monoclonal Antibody for Antibody-Mediated Kidney Transplant Rejection
| VANCOUVER, British Columbia, May 22, 2019 /PRNewswire/ -- Vitaeris Inc. (Vitaeris) today announced that eight abstracts involving or related to clazakizumab, Vitaeris’ proprietary anti-interleukin-6 humanized monoclonal antibody, have been accepted for presentation at the 2019 American Transplant Congress (ATC) taking place from June 1-5 in Boston, MA. These studies underscore Vitaeris’ commitment to developing clazakizumab to address the unmet medical needs of transplant recipients suffering from chronic active antibody-mediated rejection and patients in need of kidney transplants.
ATC 2019 Presentations on Clazakizumab Listed Chronologically:
“These presentations by our academic collaborators demonstrate our commitment to the transplant community, and the potential for clazakizumab to become a beneficial treatment for kidney transplant recipients with chronic active antibody mediated rejection of their allograft,” said Dr. Eddie Chong, Chief Medical Officer, Vitaeris. Abstracts can be accessed at the conference website: https://atcmeetingabstracts.com/search Clazakizumab has been specially engineered to remove antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. Clazakizumab has been administered in clinical trials involving over one thousand patients and has performed well against safety and efficacy criteria with acceptable tolerability in autoimmune diseases. About Vitaeris Vitaeris Inc. is a privately held, clinical-stage biopharmaceutical company based in Vancouver, Canada, focused on the development of the anti-interleukin-6 (IL-6) monoclonal antibody clazakizumab for chronic inflammatory diseases. IL-6 is a key cytokine involved in the inflammation of rheumatoid arthritis and is now being implicated in numerous other diseases characterized by chronic inflammation, including solid organ graft rejection. Clazakizumab has been studied in clinical trials involving over one thousand patients worldwide, and was licensed on an exclusive, worldwide basis from Alder Biopharmaceuticals. Vitaeris’ shareholders include key founding investor HBM Healthcare Investments, key founder Alder, Vitaeris’ co-founders and other private investors. In December 2017, Vitaeris and CSL Limited announced a strategic partnership with option to acquire. For more information about Vitaeris, visit www.vitaerisbio.com
SOURCE Vitaeris |
View original content to download multimedia:
